pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) | MicrobiomeTrials← Back to trialsNCT06253507
pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)
ENROLLING_BY_INVITATIONPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-06-25Est. Completion: 2027-03-31
Enrollment target: 10 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Primary Sclerosing Cholangitis
This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-10…
La Jolla, United StatesCompleted Jan 10, 2025
Non-Small Cell Lung CancerMedullary Thyroid CancerColon CancerAny Solid Tumor
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and pre…
Scottsdale, United StatesEst. completion Feb 14, 2025